Mupirocin

Basic Information


CAS ID: 12650-69-0
Molecular Formula: C26H44O9
Molecular Weight: 500.6 g/mol
Monoisotopic Mass: 500.2985 g/mol
Class: Small Molecule
Natural Product: No
Other Names: BRL 4910A | BRL-4910F | CENTANY | BRL 4910F | MUPIROCIN | PSEUDOMONIC ACID | MUPIROCIN CALCIUM | BACTROBAN
Analysis: Drug repositioning mechanism analysis

OH O O O O O OH OH HO


Compound Structure and Identifier


InChI: InChI=1S/C26H44O9/c1-16(13-23(30)33-11-9-7-5-4-6-8-10-22(28)29)12-20-25(32)24(31)19(15-34-20)14-21-26(35-21)17(2)18(3)27/h13,17-21,24-27,31-32H,4-12,14-15H2,1-3H3,(H,28,29)/b16-13+/t17-,18-,19-,20-,21-,24+,25-,26-/m0/s1 See All
InChI Key: MINDHVHHQZYEEK-HBBNESRFSA-N
Smiles: C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]2CO[C@@H](C\C(=C\C(=O)OCCCCCCCCC(=O)O)\C)[C@H](O)[C@@H]2O See All
Molfile: Download


Related Target



Related Fibrosis Property


Trial Record 1

ClinicalTrial ID NCT01229553 Disease Cystic fibrosis
Phase Not Applicable Status Withdrawn
First Received October 27, 2010 Last Verified June 11, 2015
Sponsor State University of New York - Upstate Medical University

Trial Record 2

ClinicalTrial ID NCT01349192 Disease Cystic fibrosis
Phase Phase 2 Status Terminated
First Received May 6, 2011 Last Verified May 15, 2017
Sponsor University of North Carolina, Chapel Hill

Trial Record 3

ClinicalTrial ID NCT01594827 Disease Cystic fibrosis
Phase Phase 2 Status Completed
First Received May 9, 2012 Last Verified February 26, 2019
Sponsor Johns Hopkins University

Related Link


PubChem: 446596
ChEMBL: CHEMBL719